August 20, 2024Open Access

Improved Survival of Advanced‐Stage Anaplastic Thyroid Cancer With Systemic Therapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Anaplastic thyroid cancer (ATC) is the most aggressive and fatal thyroid malignancy. Currently, there still exists a paucity of literature studying the relationship between available ATC-targeted therapy, immunotherapy, and survival. We aim to investigate how systemic therapies affect survival outcomes in ATC.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Evans et al. (Tue,) studied this question.

synapsesocial.com/papers/68e5b8abb6db64358755166e https://doi.org/https://doi.org/10.1002/lary.31712

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Anaplastic Transformation of Differentiated Thyroid Carcinoma2022 · 15 citations
2Changing Patterns in the Incidence and Survival of Thyroid Cancer with Follicular Phenotype—Papillary, Follicular, and Anaplastic: A Morphological and Epidemiological Study2007 · 193 citations
3Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib2013 · 83 citations
4p63 expression profiles in human normal and tumor tissues.2002 · 521 citations
5Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction2018 · 36 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo